Jonathan H Watanabe1, Terry McInnis2, Jan D Hirsch1. 1. 1 University of California San Diego, La Jolla, CA, USA. 2. 2 Value Based Care, Laboratory Corporation of America, Burlington, NC, USA.
Abstract
BACKGROUND: Public attention and recent US Congressional activity has intensified focus on escalating medication prices. However, the actual cost of medication use extends beyond the up-front cost of purchasing medicines. It also encompasses the additional medical costs of morbidity and mortality resulting from nonoptimized medication regimens, including medication nonadherence. OBJECTIVES: Applying the most current nationally representative data sources, our goal was to estimate the cost of prescription drug-related morbidity and mortality in the United States. METHODS: Total costs of nonoptimized prescription drug use and average pathway costs for a patient who experienced a treatment failure (TF), a new medical problem (NMP), or a TF and NMP were modeled in Microsoft Excel (Microsoft Corporation, Redmond, WA) and TreeAge Pro Healthcare, v2014 (TreeAge Software, Inc, Williamstown, MA), respectively. RESULTS: The estimated annual cost of prescription drug-related morbidity and mortality resulting from nonoptimized medication therapy was $528.4 billion in 2016 US dollars, with a plausible range of $495.3 billion to $672.7 billion. The average cost of an individual experiencing TF, NMP, or TF and NMP after initial prescription use were $2481 (range: $2233, $2742), $2610 (range: $2374, $2848) and $2572 (range: $2408, $2751), respectively. CONCLUSIONS: The estimated annual cost of drug-related morbidity and mortality resulting from nonoptimized medication therapy was $528.4 billion, equivalent to 16% of total US health care expenditures in 2016. We propose expansion of comprehensive medication management programs by clinical pharmacists in collaborative practices with physicians and other prescribers as an effective and scalable approach to mitigate these avoidable costs and improve patient outcomes.
BACKGROUND: Public attention and recent US Congressional activity has intensified focus on escalating medication prices. However, the actual cost of medication use extends beyond the up-front cost of purchasing medicines. It also encompasses the additional medical costs of morbidity and mortality resulting from nonoptimized medication regimens, including medication nonadherence. OBJECTIVES: Applying the most current nationally representative data sources, our goal was to estimate the cost of prescription drug-related morbidity and mortality in the United States. METHODS: Total costs of nonoptimized prescription drug use and average pathway costs for a patient who experienced a treatment failure (TF), a new medical problem (NMP), or a TF and NMP were modeled in Microsoft Excel (Microsoft Corporation, Redmond, WA) and TreeAge Pro Healthcare, v2014 (TreeAge Software, Inc, Williamstown, MA), respectively. RESULTS: The estimated annual cost of prescription drug-related morbidity and mortality resulting from nonoptimized medication therapy was $528.4 billion in 2016 US dollars, with a plausible range of $495.3 billion to $672.7 billion. The average cost of an individual experiencing TF, NMP, or TF and NMP after initial prescription use were $2481 (range: $2233, $2742), $2610 (range: $2374, $2848) and $2572 (range: $2408, $2751), respectively. CONCLUSIONS: The estimated annual cost of drug-related morbidity and mortality resulting from nonoptimized medication therapy was $528.4 billion, equivalent to 16% of total US health care expenditures in 2016. We propose expansion of comprehensive medication management programs by clinical pharmacists in collaborative practices with physicians and other prescribers as an effective and scalable approach to mitigate these avoidable costs and improve patient outcomes.
Entities:
Keywords:
administration; adverse drug reactions; clinical pharmacy; cost; drug-related problems; health care policy; medication therapy management; pharmaceutical care; pharmacist/physician issues; pharmacoeconomics
Authors: Amanda M Kibbons; Megan Peter; Josh DeClercq; Leena Choi; Jacob Bell; Jacob Jolly; Elizabeth Cherry; Bassel Alhashemi; Nisha B Shah; Autumn D Zuckerman Journal: Drugs Real World Outcomes Date: 2020-09-21
Authors: Ivy O Poon; Felicia Skelton; Lena R Bean; Dominique Guinn; Terica L Jemerson; Ngozi D Mbue; Creaque V Charles; Uche Anadu Ndefo Journal: J Patient Cent Res Rev Date: 2021-04-19
Authors: Stephanie W Ong; Sarbjit V Jassal; Eveline C Porter; Kyoyoon K Min; Akib Uddin; Joseph A Cafazzo; Valeria E Rac; George Tomlinson; Alexander G Logan Journal: Clin J Am Soc Nephrol Date: 2021-03-18 Impact factor: 8.237